A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Status:
Completed
Trial end date:
2015-09-15
Target enrollment:
Participant gender:
Summary
This trial is conducted in the United States of America (USA). The aim of the trial is to
investigate the efficacy, safety, and tolerability of once-daily subcutaneous (SC) injections
of NNC0090-2746 for 12 weeks, as an adjunct to metformin, in participants with T2D.